Advancing Next Generation Cancer Therapeutics

Azkarra Therapeutics targets pathways at the intersection of DNA Damage Repair and Immuno-Oncology

Azkarra is a precision oncology therapeutics company

The discovery of the synthetic lethal interaction between PARP inhibition and BRCA mutation by Ashworth and others has fueled considerable effort in targeting other DNA Damage Response (DDR) pathways. There is increasing evidence that the DDR influences immunity and inflammation. Founded by Alan Ashworth, PhD, FRS, Azkarra Therapeutics aims to exploit molecular targets at the intersection of DDR and immune response and develop novel therapeutics for cancer and other diseases.


PARP7 inhibition restores anti-tumor immunogenicity and promotes pro-apoptotic pathways in PARP7-dependent tumors


OGG1 inhibition leads to accumulation of DNA damage, cell cycle arrest and ultimately apoptosis in cancer cells with high reactive oxygen species (ROS). OGG1i may also reduce toxic inflammation in normal cells.


AZK-3 inhibition is a new MOA for treatment of HRD cancers

Azkarra focuses on discovering small molecule modulators of DNA damage response (DDR) pathways that enhance anti-tumor immunity

Azkarra is developing novel therapies targeting pathway molecules associated with DNA damage repair, across the multitude of DDR pathways that afford new opportunities to treat cancer.